Rapid and Simultaneous Initiation of Guideline-Directed Kidney Therapies in Patients with CKD and Type 2 Diabetes
Journal of the American Society of Nephrology · 2025
DOI: 10.1681/asn.0000000752 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of the American Society of Nephrology, 2025. Verfasst von Ahmed Mustafa Rashid und 6 weiteren Autor:innen. Beteiligte Einrichtung: Baylor Scott and White Research Institute, Baylor Scott and White Health, Dallas, Texas. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic, Diabetic Nephropathies. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 128 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Diabetes mellitus
Abstract (Originalsprache)
The global incidence of CKD continues to rise, with type 2 diabetes as a major contributor. At any stage of CKD, patients with concurrent CKD and type 2 diabetes are at heightened cardiovascular risk and have a greater likelihood of dying from cardiovascular causes than progressing to kidney failure. Consequently, the use of “four pillars” of CKD therapy, including renin-angiotensin system inhibitors, sodium-glucose cotransporter 2 inhibitor, nonsteroidal mineralocorticoid receptor antagonists, and glucagon-like peptide-1 receptor agonists, has been advocated to reduce cardiovascular-kidney risk. Although these therapies can mitigate cardiovascular and kidney events when used individually, the residual risks of these events remain high across major clinical trials testing these therapies separately as well as in real-world clinical settings. This raises the question about when to optimally initiate these therapies, including strategies that start these agents in rapid sequence, or even simultaneously, to reduce long-term risk, thereby mirroring best practices with rapid titration schedules in patients with heart failure. However, initiating all four therapies simultaneously in the setting of CKD has not yet been tested due to lack of data on safety and tolerability in this high-risk population. Data regarding the safety profile of rapid sequence initiation remain limited. Therefore, our aim was to review the existing evidence on the safety profiles of guideline-recommended therapies and discuss the challenges associated with rapid sequence initiation of these treatments in patients with CKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Baylor Scott and White Research Institute, Baylor Scott and White Health, Dallas, Texas.
- Baylor Scott and White: The Heart Hospital Plano, Plano, Texas.
- Department of Medicine, Baylor College of Medicine, Temple, Texas.
- Division of Nephrology, Department of Medicine, Toronto General Hospital, Toronto, Ontario, Canada.
- Division of Nephrology, Department of Internal Medicine, Baylor University Medical Center, Dallas, Texas.
- Department of Medicine, Veterans Affairs Medical Center, Washington, DC.
ORCID-Profile: Tariq Shafi
Zitieren
APA
Rashid, A. M., Khan, M. S., Cherney, D. Z. I., Mehta, A., Rangaswami, J., Shafi, T., & Butler, J. (2025). Rapid and Simultaneous Initiation of Guideline-Directed Kidney Therapies in Patients with CKD and Type 2 Diabetes. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.0000000752
Vancouver
Rashid AM, Khan MS, Cherney DZI, Mehta A, Rangaswami J, Shafi T, et al. Rapid and Simultaneous Initiation of Guideline-Directed Kidney Therapies in Patients with CKD and Type 2 Diabetes. Journal of the American Society of Nephrology. 2025. doi:10.1681/asn.0000000752
BibTeX
@article{Rashid2025,
author = {Rashid, Ahmed Mustafa and Khan, Muhammad Shahzeb and Cherney, David Z I and Mehta, Ankit and Rangaswami, Janani and Shafi, Tariq and Butler, Javed},
title = {Rapid and Simultaneous Initiation of Guideline-Directed Kidney Therapies in Patients with CKD and Type 2 Diabetes},
journal = {Journal of the American Society of Nephrology},
year = {2025},
doi = {10.1681/asn.0000000752}
}
EUVIMED